RMD Stock Recent News

Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher on Friday.

ResMed easily beat Wall Street's earnings estimates for its fiscal Q3. The company's products are enjoying strong demand.

ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.

The medical devices company beat expectations for its fiscal third quarter.

ResMed Inc. (NYSE:RMD ) Q3 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Dan Hurren - MST Marquee Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Bailey - Macquarie Anthony Petrone - Mizuho Group Suraj Kalia - Oppenheimer Margaret Kaczor-Andrew - William Blair Gretel Janu - E&P Brett Fishbin - KeyBanc Mike Matson - Needham & Company Lyanne Harrison - Bank of America Steve Wheen - Jarden Saul Hadassin - Barrenjoey Capital Mike Toomey - Jefferies Operator Hello. And welcome to the Q3 Fiscal Year 2024 ResMed Earnings Conference Call.

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed (RMD) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.68 per share a year ago.

ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.